RxDoctor Payments Data

Katie Wooten, NP

Family · Dalton, GANPI 1003281171

Payments from drug & device makers

$1,322in general payments, 2019–2025

Across 62 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$259
  • Insulet Corporation$240
  • Tandem Diabetes Care, Inc.$126
  • Corcept Therapeutics$102
  • Dexcom, Inc.$97
  • Novo Nordisk$80
  • plus $418 from 12 others

What the payments were for

  • Food & beverage$1,322100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,322 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$40,626
Medicare patients
203
Services billed
1,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide230$262,554
OzempicSemaglutide124$171,227
JardianceEmpagliflozin90$86,517
Tresiba Flextouch U-200Insulin Degludec66$74,361
TrulicityDulaglutide41$50,105
FarxigaDapagliflozin Propanediol67$48,927
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$40,304
Tresiba Flextouch U-100Insulin Degludec49$29,737
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog40$26,068
Fiasp FlextouchInsulin Aspart (Niacinamide)29$23,098
Humulin R U-500 KwikpenInsulin Regular, Human15$21,932
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$16,966
Humalog Kwikpen U-100Insulin Lispro53$14,913
Novolog FlexpenInsulin Aspart58$11,063
Insulin Lispro Kwikpen U-100Insulin Lispro24$8,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$24$318,316301 claims
Novo NordiskOzempic, Novolog$80$178,878145 claims
Boehringer IngelheimJardiance, Tradjenta$18$95,029104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.

Other family in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →